ASCO 2021—an update on metastastic colorectal cancer
نویسندگان
چکیده
Summary The 2021 ASCO Annual Meeting provided updates on novel therapies in rare subgroups of metastatic colorectal cancer, such as immunotherapy microsatellite instable cancer and antibody–drug conjugate therapy HER2-positive disease. Furthermore, the concept anti-EGFR rechallenge has received additional momentum with data from CHRONOS trial regard to treating patients later lines well how integrate analysis circulating tumor DNA clinical decision-making.
منابع مشابه
ASCO update: lung cancer
In the past few years there have been major changes in the treatment landscape in oncology; lung cancer is affected by those changes like almost no other solid tumor. The rise of further second- and third-line tyrosine kinase inhibitors offers sequential therapy for patients with mutated non-small-cell lung cancer. Immunotherapy has found its way into clinical routine and presents us with new c...
متن کاملASCO 2016 – update colorectal liver metastases
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study,...
متن کاملASCO update on lymphoma
s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.
متن کاملUpdate on Hereditary Colorectal Cancer.
In the past two decades, significant advances have been made in our understanding of colorectal (CRC) tumors with DNA mismatch (MMR) repair deficiency. The knowledge from molecular and genetic alterations in a variety of clinical conditions has refined the disease terminology and classification. Hereditary non-polyposis colorectal cancer (HNPCC) encompasses a spectrum of conditions that have si...
متن کاملASCO-update: gastrointestinal tumors
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Memo – Magazine of European Medical Oncology
سال: 2021
ISSN: ['1865-5041', '1865-5076']
DOI: https://doi.org/10.1007/s12254-021-00763-9